Author of

• 15382

  +

  P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15452

    +

    P3.04-070 - Early Prognostic Significance of Circulating Laminin γ2-Chain Fragment in Non-Small-Cell Lung Cancer (ID 3164)

    09:30 - 09:30  |  Author(s): X. Zhao
    • Abstract

    Background:
    Laminin γ2-chain (LN-γ2), a distinctive subunit of heterotrimeric laminin-332, is frequently up-regulated in various types of carcinomas, and is of great importance in the biological processes including cell migration and tumor invasion. Despite of this, the status of circulating LN-γ2 fragment in lung cancer patients is still uncertain.
    
    Methods:
    In this study, serum samples from 538 all-stage (stage I-IV) patients of non-small-cell lung cancer (NSCLC) and 94 age-matched normal volunteers were determined by enzyme-linked immunosorbent assay. Data were statistically analyzed in combination with clinicopathological information.
    
    Results:
    Compared to the normal controls, serum LN-γ2 concentration is drastically increased in NSCLC patients (P < 0.001), even in early cases of stage I patients (P < 0.001). Furthermore, our data suggested that serum LN-γ2 level was in close correlation to male gender (P < 0.001) and smoking status (P < 0.001) with a higher positive rate relative to each counterpart, but was not significant between adenocarcinoma and squamous cell carcinoma histologies (P = 0.879). We also found that circulating LN-γ2 could reflect the progression of lung cancer with higher serum levels or positive rates in higher tumor-node-metastasis (TNM) stages. Survival analysis on 370 eligible patients who underwent a follow-up examination up to 4 years indicated that patients of serum LN-γ2 positive group survived markedly shorter compared with those in the negative group (P = 0.028), and it was especially the case for clinical stage I (N = 72, P < 0.001) and stage T1 (N = 67, P = 0.001), even for stage N0 patients (N = 148, P = 0.038), which all represent groups of early cases. As for the patients of advanced stages, however, it was not the case that the overall survival rates between LN-γ2 positive and negative patients were not significantly different among clinical stages II-IV (P = 0.830), stages T2-4 (P = 0.575), stages N1-3 (P = 0.669), and stage M1 (P = 0.849) groups, respectively. Subsequently, Cox regression analysis was performed to define serum LN-γ2 as an independent prognostic indicator in the all-stage NSCLC cases (N = 370, univariate, P = 0.035; multivariate, P = 0.007). Worthy of note, however, in the multivariate analysis on those more advanced cases (stage II-IV), no statistical significance was observed on the serum levels of Ln-γ2 (N = 298, P = 0.234).
    
    Conclusion:
    In summary, our study suggests circulating LN-γ2 to be a promising diagnostic biomarker for early-stage NSCLC and an effective indicator of tumor progression. It is proposed that circulating LN-γ2 might be important and applicable for the prognosis of early-stage NSCLC patients, rather than that of advanced cases.